Nora Therapeutics Company
Nora Therapeutics is a specialty biopharmaceutical company developing therapeutics to address clinical unmet needs in reproductive medicine. Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.
Technology:
Longevity FemTech
Industry:
Biotechnology, Health Care, Medical Device
Headquarters:
Palo Alto California, United States
Founded Date:
6-29
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
5
Total Funding:
$36.8M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series B
Register and Claim Ownership